Relationship Between Major Depressive Disorder (Mdd) Symptoms and Mdd Heterogeneity

被引：0
|
作者：
Huang, Lianyun [1 ]
Tang, Sonja [2 ]
Krebs, Morten Dybdahl [3 ,4 ]
Schork, Andrew J. [3 ,4 ,5 ]
Werge, Thomas M. [3 ,4 ,6 ]
Dahl, Andy [7 ]
Zuber, Verena [2 ]
Cai, Na [1 ]
机构：
[1] Helmholtz Zentrum Munchen, Helmholtz Pioneer Campus, Neuherberg, Germany
[2] Imperial Coll London, Dept Epidemiol & Biostat, London, England
[3] Mental Hlth Ctr Sct Hans, Inst Biol Psychiat, Roskilde, Denmark
[4] Lundbeck Fdn Initiat Integrat Psychiat Res iPSYCH, Copenhagen, Denmark
[5] Translat Genom Res Inst TGEN, Neurogen Div, Phoenix, AZ USA
[6] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
[7] Univ Chicago, Sect Genet Med, Chicago, IL 60637 USA
来源：
GENETIC EPIDEMIOLOGY | 2021年 / 45卷 / 07期
关键词：
D O I：
暂无
中图分类号：
Q3 [遗传学];
学科分类号：
071007 ; 090102 ;
摘要：
48
引用
收藏
页码：761 / 761
页数：1
相关论文
共 50 条
  • [31] Response to D-amphetamine is altered in major depressive disorder (MDD).
    Tremblay, LK
    Busto, U
    Naranjo, CA
    Cardenas, L
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 130 - 130
  • [32] Volume of the midbrain dorsal raphe nucleus in major depressive disorder (MDD)
    Stockmeier, CA
    Saenz, MD
    Smith, E
    Miguel-Hidalgo, JJ
    Friedman, L
    Rajkowska, G
    BIOLOGICAL PSYCHIATRY, 2005, 57 (08) : 183S - 183S
  • [33] Blunted d-amphetamine response in major depressive disorder (MDD).
    Tremblay, LK
    Naranjo, CA
    Busto, U
    Cardenas, L
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 141 - 141
  • [34] DEVELOPMENT AND CONTENT VALIDITY OF A PATIENT REPORTED OUTCOMES MEASURE TO ASSESS SYMPTOMS OF MAJOR DEPRESSIVE DISORDER (MDD)
    Hassan, M.
    Lasch, K. E.
    Piault-Louis, E.
    Jernigan, K.
    Hwang, S.
    Fitz-randolph, M.
    Pathak, S.
    Locklear, J.
    Endicott, J.
    VALUE IN HEALTH, 2011, 14 (07) : A295 - A295
  • [35] Longitudinal assessment of sleep neurophysiology in adolescent major depressive disorder (MDD)
    Castiglione, Chiara
    Markovic, Andjela
    Wild, Salome
    Zarafeta, Dimitra
    Kaess, Michael
    Tarokh, Leila
    JOURNAL OF SLEEP RESEARCH, 2024, 33
  • [36] ECONOMIC ANALYSIS OF ESCITALOPRAM (GENERIC DRUG) IN MAJOR DEPRESSIVE DISORDER (MDD)
    Walczak, J.
    Nogas, G.
    Garbacka, M.
    Obrzut, G.
    Pieniazek, I
    VALUE IN HEALTH, 2010, 13 (03) : A114 - A114
  • [37] Efficacy and safety of sertraline in the treatment of pediatric major depressive disorder (MDD)
    Wagner, K
    Donnelly, C
    Wohlberg, C
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S231 - S232
  • [38] Adjunctive aripiprazole in major depressive disorder (MDD): efficacy and predictors of remission
    Nelson, J. C.
    Thase, M. E.
    Baker, R. A.
    Rollin, L. M.
    McQuade, R. D.
    Marcus, R. N.
    Berman, R. M.
    Wisniewski, S. R.
    Gismondi, R.
    Loze, J. Y.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S386 - S386
  • [39] Major depressive disorder (mdd): emerging immune targets at preclinical level
    Varma, Manasi
    Kaur, Arshpreet
    Bhandari, Ranjana
    Kumar, Ashwani
    Kuhad, Anurag
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2023, 27 (06) : 479 - 501
  • [40] COST AND RESOURCE USE OF MANAGING MAJOR DEPRESSIVE DISORDER (MDD) IN CHINA
    Low, W.
    Azmi, S.
    Yee, S. L.
    Abdat, A.
    Yang, Y.
    Milea, D.
    VALUE IN HEALTH, 2014, 17 (07) : A768 - A769
12345